Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms

Pharmacogenomics

Volumn 12, Issue 10, 2011, Pages 1417-1427

  Tzvetkov, Mladen V ^a   Behrens, Gerrit ^a   O'Brien, Valerie P ^a   Hohloch, Karin ^a   Brockmöller, Jürgen ^a   Benhr, Peter ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

cisplatin; DNA repair; ERCC1; nephrotoxicity; OCT2; organic cation transporter; polymorphisms

Indexed keywords

ADENINE; ASPARAGINE; CISPLATIN; CYTOSINE; DOCETAXEL; IRINOTECAN; PACLITAXEL;

ADULT; AGED; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COHORT ANALYSIS; DNA POLYMORPHISM; DRUG MEGADOSE; EPO GENE; ERCC1 GENE; ESOPHAGUS CANCER; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; GSTM1 GENE; GSTT1 GENE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LARP2 GENE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OCT1 GENE; OCT2 GENE; PHARMACOGENETICS; PROSPECTIVE STUDY; RENAL PROTECTION; SIDE EFFECT; STOMACH CANCER; XRCC1 GENE;

ADULT; AGED; ALLELES; CISPLATIN; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; GLOMERULAR FILTRATION RATE; HAPLOTYPES; HOMOZYGOTE; HUMANS; KIDNEY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80054883716     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.93     Document Type: Article

References (54)

1. Arany I, Safirstein Rl. Cisplatin nephrotoxicity. Semin. Nephrol. 23(5), 460-464 (2003). (Pubitemid 37176691)
2. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 73(9), 994-1007 (2008). (Pubitemid 351543900)
3. Benohr P, Grenz A, Hartmann JT, Muller GA, Blaschke S. Cystatin C-a marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy. Kidney Blood Press. Res. 29(1), 32-35 (2006). (Pubitemid 43875170)
4. Sahni V, Choudhury D, Ahmed Z. Chemotherapy-associated renal dysfunction. Nat. Rev. Nephrol. 5(8), 450-462 (2009).
5. Oldenburg J, Kraggerud SM, Brydoy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-S-transferase-p1 and-m1, a retrospective cross sectional study. J. Transl. Med. 5, 70 (2007).
6. Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J. Clin. Oncol. 25(6), 708-714 (2007). (Pubitemid 350002927)
7. Ott K, Lordick F, Becker K et al. Glutathione-S-transferase p1, t1 and m1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: Gstm1-present genotype is associated with better prognosis in completely resected patients. Int. J. Colorectal. Dis. 23(8), 773-782 (2008).
8. Ciarimboli G, Ludwig T, Lang D et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 167(6), 1477-1484 (2005). (Pubitemid 41713303)
9. Ciarimboli G, Deuster D, Knief A et al. Organic cation transporter 2 mediates cisplatin-induced oto-and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 176(3), 1169-1180
10. Zolk O, Solbach TF, Konig J, Fromm MF. Structural determinants of inhibitor interaction with the human organic cation transporter oct2 (slc22a2). Naunyn Schmiedebergs Arch. Pharmacol. 379(4), 337-348 (2009).
11. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (slc22a1-3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther. 319(2), 879-886 (2006).
12. Tzvetkov MV, Vormfelde SV, Balen D et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Ther. 86(3), 299-306 (2009).
13. Fichtinger-Schepman Am, van der Veer JL, Den Hartog JH, Lohman PH, Reedijk J. Adducts of the antitumor drug cis-diammined ichloroplatinum(ii) with DNA: Formation, identification, and quantitation. Biochemistry 24(3), 707-713 (1985).
14. Shukla SJ, Duan S, Badner JA, Wu X, Dolan ME. Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet. Genomics 18(3), 253-262 (2008). (Pubitemid 351323240)
15. Vogel U, Dybdahl M, Frentz G, Nexo BA. DNA repair capacity: inconsistency between effect of over-expression of five NER genes and the correlation to mrna levels in primary lymphocytes. Mutat. Res. 461(3), 197-210 (2000).
16. Cummings M, Higginbottom K, Mcgurk CJ et al. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin c in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem. Pharmacol. 72(2), 166-175 (2006). (Pubitemid 43870167)
17. Lord RV, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8(7), 2286-2291 (2002). (Pubitemid 34753602)
18. Viguier J, Boige V, Miquel C et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. 11(17), 6212-6217 (2005). (Pubitemid 41262950)
19. Pare L, Marcuello E, Altes A et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br. J. Cancer 99(7), 1050-1055 (2008).
20. Zhou W, Gurubhagavatula S, Liu G et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 10(15), 4939-4943 (2004). (Pubitemid 39099767)
21. Krivak TC, Darcy KM, Tian C et al. Relationship between ERCC1 polymorphisms, disease progression, and survival in the gynecologic oncology group Phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage iii epithelial ovarian cancer. J. Clin. Oncol. 26(21), 3598-3606 (2008).
22. Suk R, Gurubhagavatula S, Park S et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin. Cancer Res. 11(4), 1534-1538 (2005). (Pubitemid 40315237)
23. Bradbury PA, Kulke MH, Heist RS et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet. Genomics 19(8), 613-625 (2009).
24. Ryu JS, Hong YC, Han HS et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44(3), 311-316 (2004).
25. Popov AF, Schulz EG, Schmitto JD et al. Relation between renal dysfunction requiring renal replacement therapy and promoter polymorphism of the erythropoietin gene in cardiac surgery. Artif. Organs 34(11), 961-968 (2010).
26. Tong Z, Yang Z, Patel S et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc. Natl Acad. Sci. USA 105(19), 6998-7003 (2008). (Pubitemid 351754519)
27. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 86(4), 396-402 (2009).
28. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 10(1), 54-61 (2010).
29. Mosteller RD. Simplified calculation of body-surface area. N. Engl. J. Med. 317(17), 1098 (1987).
30. Stevens LA, Coresh J, Schmid CH et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am. J. Kidney Dis. 51(3), 395-406 (2008). (Pubitemid 351273480)
31. Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmoller J. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J. DOI: 10.1038/tpj.2010.75 (2010) (Epub ahead of print).
32. Tzvetkov MV, Meineke I, Sehrt D, Vormfelde SV, Brockmoller J. Amelogenin-based sex identification as a strategy to control the identity of DNA samples in genetic association studies. Pharmacogenomics 11(3), 449-457 (2010).
33. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and visualization of ld and haplotype maps. Bioinformatics 21(2), 263-265 (2005). (Pubitemid 40202029)
34. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73(5), 1162-1169 (2003). (Pubitemid 37414228)
35. Ciarimboli G, Holle SK, Vollenbrocker B et al. New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2. Mol. Pharm. 8(1), 270-279 (2011).
36. Franke RM, Kosloske AM, Lancaster CS et al. Influence of OCT1/OCT2-deficiency on cisplatin-induced changes in urinary N-acetyl-b-d-glucosaminidase. Clin. Cancer Res. 16(16), 4198-4206
37. Imamura Y, Murayama N, Okudaira N et al. Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion. Clin. Pharmacol. Ther. 89(1), 81-88 (2011).
38. Urakami Y, Kimura N, Okuda M, Inui K. Creatinine transport by basolateral organic cation transporter HOCT2 in the human kidney. Pharm. Res. 21(6), 976-981 (2004). (Pubitemid 38870147)
39. Osawa K. SNPs in ERCC1 and drug response to cisplatin in non-small-cell lung cancer patients. Pharmacogenomics 12(4), 445-447.
40. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ercc1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355(10), 983-991 (2006). (Pubitemid 44343542)
41. Vilmar A, Santoni-Rugiu E, Sorensen JB. ERCC1, toxicity and quality of life in advanced nsclc patients randomized in a large multicentre Phase III trial. Eur. J. Cancer 46(9), 1554-1562 (2010).
42. Yu JJ, Mu C, Lee KB et al. A nucleotide polymorphism in ercc1 in human ovarian cancer cell lines and tumor tissues. Mutat. Res. 382(1-2), 13-20 (1997). (Pubitemid 28376643)
43. Yu JJ, Lee KB, Mu C et al. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol. 16(3), 555-560 (2000).
44. Huang ZH, Hua D, Du X et al. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J. Gastroenterol. 14(41), 6401-6407 (2008).
45. Yang M, Kim WH, Choi Y et al. Effects of ERCC1 expression in peripheral blood on the risk of head and neck cancer. Eur. J. Cancer Prev. 15(3), 269-273 (2006). (Pubitemid 43791775)
46. Woelfelschneider A, Popanda O, Lilla C et al. A distinct ERCC1 haplotype is associated with mrna expression levels in prostate cancer patients. Carcinogenesis 29(9), 1758-1764 (2008).
47. Hur H, Song K, Park C, Hong Y, Chun H, Jeon H. Polymorphism of nucleotide excision repair genes as predictors for clinical outcome in advanced gastric cancer patients treated with oxaliplatin-based chemotherapy. J. Clin. Oncol. 27, 15s (2009) (Abstract 4565).
48. Li Y, Gu S, Wu Q et al. No association of ercc1 c8092a and t19007c polymorphisms to cancer risk: a meta-analysis. Eur. J. Hum. Genet. 15(9), 967-973 (2007). (Pubitemid 47308473)
49. Marsh S, Paul J, King CR, Gifford G, Mcleod HL, Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the scottish randomised trial in ovarian cancer. J. Clin. Oncol. 25(29), 4528-4535 (2007). (Pubitemid 350035308)
50. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 10(1), 54-61 (2010).
51. Loos WJ, de Jongh FE, Sparreboom A et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J. Clin. Oncol. 24(10), 1499-1506 (2006). (Pubitemid 46638770)
52. Leabman MK, Huang CC, Kawamoto M et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 12(5), 395-405 (2002). (Pubitemid 34816419)
53. Kottgen A, Pattaro C, Boger CA et al. New loci associated with kidney function and chronic kidney disease. Nat. Genet. 42(5), 376-384
54. Huang Q, Dunn RT 2nd, Jayadev S et al. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol. Sci. 63(2), 196-207 (2001). (Pubitemid 32982793)